miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi
NCT ID: NCT01444560
Last Updated: 2012-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
21 participants
OBSERVATIONAL
2008-12-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Microarray Analysis of microRNA Expression in Basal Cell Carcinoma
NCT01498250
Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi
NCT00862914
Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma
NCT01500954
Role of microRNA in the Development of Cutaneous Squamous Cell Carcinoma
NCT01143311
Expression Levels of microRNA Processing Enzymes Dicer and Drosha in Epithelial Skin Cancer
NCT00849914
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cutaneous Melanoma
No interventions assigned to this group
Cutaneous Melanoma Metastases
No interventions assigned to this group
Benign Melanocytic Nevi
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* cutaneous melanoma metastases
* benign melanocytic nevi
Exclusion Criteria
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruhr University of Bochum
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael Sand
Postdoc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Falk G Bechara, PD Dr.
Role: STUDY_DIRECTOR
Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Bochum, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sand M, Skrygan M, Georgas D, Sand D, Gambichler T, Altmeyer P, Bechara FG. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell Tissue Res. 2012 Oct;350(1):119-26. doi: 10.1007/s00441-012-1446-0. Epub 2012 Jun 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
microRNA4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.